Table 1.
Comparison of baseline information.
| group | Cases (n) | Gender (M/F) | Stage |
|||
|---|---|---|---|---|---|---|
| StageⅡ | StageⅢ | StageⅣa | StageⅣb | |||
| Resistant group | 36 | 28/9 | 17 | 11 | 6 | 2 |
| Sensitive group | 21 | 17/3 | 13 | 5 | 2 | 1 |
| value | 0.679 | 0.426 | −0.728 | |||
| P value | >0.05 | >0.05 | >0.05 | |||
Comparison of baseline information.
| group | Cases (n) | Gender (M/F) | Stage |
|||
|---|---|---|---|---|---|---|
| StageⅡ | StageⅢ | StageⅣa | StageⅣb | |||
| Resistant group | 36 | 28/9 | 17 | 11 | 6 | 2 |
| Sensitive group | 21 | 17/3 | 13 | 5 | 2 | 1 |
| value | 0.679 | 0.426 | −0.728 | |||
| P value | >0.05 | >0.05 | >0.05 | |||